Hikma Pharmaceuticals PLC (LON:HIK)
1,476p-0.07%
Spriggl Score: Good— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Injectables moat intact despite revenue cut; low valuation offers safety pending margin stability.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injecta…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - Specialty & Generic
- Market Cap:
- £3.1B
Recent dividends
- 19 Mar 202636.48p
- 14 Aug 202526.75p
- 20 Mar 202537.21p
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Hikma Pharmaceuticals PLC and 1,600+ UK and US stocks.
Start free